These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 5311514)

  • 21. [Outcome of osseous lesions of hyperparathyroidism in a patient with chronic renal failure treated with high doses of vitamin D].
    Verberckmoes R; Tanghe W; Michielsen P; Vandenbroucke J
    J Urol Nephrol (Paris); 1970 Sep; 76(9):790-7. PubMed ID: 5482082
    [No Abstract]   [Full Text] [Related]  

  • 22. Vitamin D compounds and renal osteodystrophy.
    Felsenfeld AJ; Llach F
    Int J Artif Organs; 1983 Nov; 6(6):281-4. PubMed ID: 6689416
    [No Abstract]   [Full Text] [Related]  

  • 23. Calcium and phosphorus metabolism in chronic uremia.
    Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
    Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Disorders of calcium metabolism in kidney failure].
    Ritz E; Krempien B; Andrassy K
    Med Klin; 1972 Sep; 67(36):1129-32. PubMed ID: 4561354
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium metabolism in chronic renal failure.
    Kaye M; Silverman M
    J Lab Clin Med; 1965 Oct; 66(4):535-48. PubMed ID: 5843082
    [No Abstract]   [Full Text] [Related]  

  • 27. Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.
    Besarab A; Caro JF; Ihle BU; Burke JF; Glennon JA; Fischer JA
    Nephron; 1981; 27(3):127-33. PubMed ID: 7219643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Parathyroid and bone. Calcimimetics and bone metabolism].
    Fukumoto S
    Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dihydrotachysterol (DHT) and supplemental calcium therapy in dialysis patients.
    Kliger AS; Yap P; Jensen P; Finkelstein FO
    Proc Clin Dial Transplant Forum; 1976 Nov 19-22; 6():184-90. PubMed ID: 1029884
    [No Abstract]   [Full Text] [Related]  

  • 30. Control of severe hyperparathyroidism and regression of a brown tumour after treatment with i.v. alfacalcidol in a uraemic patient.
    Mourad G; Argilés A; Vela C; Lorho R; Flavier JL; Canaud B; Mion CM
    Nephrol Dial Transplant; 1995; 10(4):552-4. PubMed ID: 7624003
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dialysis bone disease associated with secondary hyperparathyroidism].
    Nakazawa R
    Nihon Rinsho; 1992 Jan; 50 Suppl():783-8. PubMed ID: 1578767
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D; Kraft D; Schaefer K; Krempien B
    MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of bone disease in patients on chronic hemodialysis with dihydrotachysterol.
    Cordy PE
    Trans Am Soc Artif Intern Organs; 1976; 22():60-4. PubMed ID: 951878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of bone disease with dihydrotachysterol in patients undergoing long-term hemodialysis.
    Cordy PE
    Can Med Assoc J; 1977 Oct; 117(7):766-8. PubMed ID: 907948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyrocalcitonin: physiological importance and significance in renal failure.
    Munson PL
    Am J Med Sci; 1971 Dec; 262(6):310-9. PubMed ID: 4947826
    [No Abstract]   [Full Text] [Related]  

  • 37. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure.
    Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA
    Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of osteitis fibrosa with 1,25-dihydroxycholecalciferol in patients in treatment with periodic hemodialysis. Effects on the hematochemical and radiological picture].
    Docci D; Turci F; Salvi G; Pistocchi E; Pretolani E
    G Clin Med; 1982; 63(11-12):831-40. PubMed ID: 6897817
    [No Abstract]   [Full Text] [Related]  

  • 39. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of bone resorptions following treatment of renal osteitis fibrosa.
    Ellis HA
    Am J Surg Pathol; 1988 Apr; 12(4):325-6. PubMed ID: 3354757
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.